Drug data last refreshed 18h ago · AI intelligence enriched 4d ago
DDAVP (desmopressin acetate) is a synthetic vasopressin analogue administered via injection used to treat central diabetes insipidus, nocturnal enuresis, and hemophilia A. It works by replacing or mimicking endogenous antidiuretic hormone (ADH) to increase water reabsorption in the kidneys and promote clotting factor release.
Product approaching loss of exclusivity with moderate competitive pressure (60/100), indicating potential team consolidation and shift toward generic/biosimilar management strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia
Desmopressin Acetate 0.2 mg Tablets, Fasting
Only 2 linked positions available for DDAVP, predominantly in HR and organizational development rather than commercial or medical roles, reflecting the product's mature stage and sponsor's operational focus. Career progression here involves supporting organizational initiatives and culture management rather than product-driven sales or medical affairs growth.
Worked on DDAVP at Nordic Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
2 open roles linked to this drug
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo